Advanced Technology Platform For Stem Cell-Derived Exosomes Manufacturing Process

By Elie Zakhem, Jae Jung, Cameron Garland, and Michael Boychyn, RoosterBio and Lauren Torres, Mario Sinani, Carl Breuning, Jeremy Neidert, and Rachel Legmann, Repligen

In recent years, there has been a significant surge in the demand for Extracellular Vesicle (EV) supply, driven by their emerging role as crucial intercellular messengers and their promising therapeutic potential. EVs, particularly those derived from mesenchymal stem cells (MSC-EVs), have garnered attention for their ability to serve as natural and highly specific drug delivery vehicles, which offer enhanced efficiency in targeted therapies. This growing interest is reflected in the increasing number of clinical trials exploring the use of MSC-EVs in both therapeutic applications and skincare products. However, meeting this rising demand presents several challenges. The inherent complexity and fragility of EVs, along with issues related to the scalability, yield, and purity of production processes, pose significant obstacles to large-scale manufacturing.

Gain insight into two scalable production platforms designed to enhance the efficiency and reliability of EV production to support the expanding clinical and commercial applications of these biologically potent vesicles.